Top

15-04-2018 | Breast cancer | Article

Immunotherapy in Breast Cancer: the New Frontier

Journal: Current Breast Cancer Reports

Authors: Zishuo I. Hu, Heather L. McArthur

Abstract

Purpose of review

This review summarizes current immunotherapies in breast cancer, with an emphasis on immune checkpoint inhibitors and vaccines.

Recent findings

Combination immunotherapy with checkpoint inhibitors and cytotoxic therapies have shown promising results. Active clinical trials are ongoing in both early stage and metastatic settings for triple negative, HER2+, and hormone-positive breast cancer patients.

Summary

Ongoing challenges remain in defining biomarkers that predict response to immunotherapy, determining the optimal combination immunotherapies, and enhancing the immunogenicity of breast cancer subtypes.

O’Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science. 2010;327:1098–102. https://doi.org/10.1126/science.1178334.CrossRefPubMedPubMedCentral

Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271:1734–6. https://doi.org/10.1126/science.271.5256.1734.CrossRefPubMed

Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207–12. https://doi.org/10.1016/j.coi.2011.12.009.CrossRefPubMedPubMedCentral

Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res: Off J Am Assoc Cancer Res. 2010;16:3485–94. https://doi.org/10.1158/1078-0432.CCR-10-0505.CrossRef

McArthur HL, Diab A, Page DB, et al. A pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling. Clin Cancer Res: Off J Am Assoc Cancer Res. 2016;22:5729–37. https://doi.org/10.1158/1078-0432.CCR-16-0190.CrossRef

Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, et al. Deep sequencing of T-cell receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res. 2016;4:835–44. https://doi.org/10.1158/2326-6066.CIR-16-0013.CrossRefPubMedPubMedCentral

Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:2460–7. https://doi.org/10.1200/JCO.2015.64.8931.CrossRef

Emens LA, Braiteh FS, Cassier P, Delord JP, Eder JP, Fasso M, et al. Abstract 2859: inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Res. 2015;75:2859. https://doi.org/10.1158/1538-7445.AM2015-2859.CrossRef

Schmid P, Cruz C, Braiteh FS, Eder JP, Tolaney S, Kuter I, et al. Abstract 2986: atezolizumab in metastatic TNBC (mTNBC): long-term clinical outcomes and biomarker analyses. Cancer Res. 2017;77:2986. https://doi.org/10.1158/1538-7445.AM2017-2986.CrossRef

10.

Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat 2017.

11.

Adams S, Loi S, Toppmeyer D, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): preliminary data from KEYNOTE-086 cohort B. J Clin Oncol. 2017;35:1088.CrossRef

12.

Adams S, Schmid P, Rugo HS, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol. 2017;35:1008.CrossRef

13.

Adams S, Diamond JR, Hamilton EP, et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). 2016 ASCO Annual Meeting 2016. J Clin Oncol, 2016;34:(suppl; abstr 1009).

14.

Tolaney S, Savulsky C, Aktan G, et al. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Eur J Cancer. 2017;72:S16. https://doi.org/10.1016/S0959-8049(17)30131-4.CrossRef

15.

Nanda R, Liu MC, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. J Clin Oncol. 2017;35:506.CrossRef

16.

Schmid P, Park YH, Muñoz-Couselo E, et al. Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173. J Clin Oncol. 2017;35:556.CrossRef

17.

Schmid P, Cortes Castan J, Bergh J, et al. 233TiPKEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC). Ann Oncol. 2017;28:mdx364.015-mdx364.015. https://doi.org/10.1111/dom.13279.CrossRef

18.

Rugo H, Delord J-P, Im S-A, et al. Abstract S5-07: preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 2016;76:S5-07-S5. https://doi.org/10.1093/annonc/mdy012.CrossRef

19.

Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–6. https://doi.org/10.1038/74704.CrossRefPubMed

20.

Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160–70. https://doi.org/10.1016/j.ccr.2010.06.014.CrossRefPubMedPubMedCentral

21.

Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A. 2011;108:7142–7.CrossRefPubMedPubMedCentral

22.

Loi S, Giobbe-Hurder A, Gombos A et al. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study. 2017 SABCS. San Antonio, Texas 2017.

23.

McArthur H, Beal K, Halpenny D, Henrich M, Modi S, Patil S, et al. Abstract 4705: CTLA4 blockade with HER2-directed therapy (H) yields clinical benefit in women undergoing radiation therapy (RT) for HER2-positive (HER2+) breast cancer brain metastases (BCBM). Cancer Res. 2017;77:4705. https://doi.org/10.1158/1538-7445.AM2017-4705.CrossRef

24.

McArthur HL, Barker CA, Gucalp A et al. A single-arm, phase II study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC). 2018 ASCO-SITC Clinical Immuno-Oncology Symposium 2017.

25.

Kok M, Horlings HM, van de Vijver K, et al. LBA14 Adaptive phase II randomized non-comparative trial of nivolumab after induction treatment in triple negative breast cancer: TONIC-trial. Ann Oncol. 2017;28:mdx440.006-mdx440.006. https://doi.org/10.1186/s12961-018-0294-0.CrossRef

26.

Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016;7:66192–201. https://doi.org/10.18632/oncotarget.11751.CrossRefPubMedPubMedCentral

27.

Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16:1092–100. https://doi.org/10.1634/theoncologist.2010-0307.CrossRefPubMedPubMedCentral

28.

Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011;17:7164–73. https://doi.org/10.1158/1078-0432.CCR-11-0649.CrossRef

29.

Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, et al. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol. 2015;1:1087–95. https://doi.org/10.1001/jamaoncol.2015.2736.CrossRefPubMed

30.

Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5911–8. https://doi.org/10.1200/JCO.2009.23.3494.CrossRef

31.

Chen G, Leatherman JM, Sunay ME, Emens LA. Abstract 4749: cyclophosphamide induces dose dependent apoptosis of CD4+FoxP3+ regulatory T cells relative to CD4+FoxP3- effector T cells in breast cancer patients. Cancer Res. 2013;73:4749.CrossRef

32.

Chen G, Gupta R, Petrik S, Laiko M, Leatherman JM, Asquith JM, et al. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014;2:949–61. https://doi.org/10.1158/2326-6066.CIR-14-0058.CrossRefPubMedPubMedCentral

33.

Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–87. https://doi.org/10.1038/nrc.2016.36.CrossRefPubMedPubMedCentral

Medicine Matters Oncology

Abstract

Purpose of review

Recent findings

Summary